GJA10: A Potential Drug Target and Biomarker for Gap Junction Protein Alpha 10

Target Name: GJA10

NCBI ID: G84694

GJA10

GJA10: A Potential Drug Target and Biomarker for Gap Junction Protein Alpha 10

Gap junction protein alpha 10 (GJA10) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key protein in the formation of gap junctions, which are specialized junctions that allow cells to communicate with one another and are involved in various physiological processes, including neuronal communication and the regulation of ion and water transport.

GJA10 has been identified as a potential drug target due to its involvement in various diseases, including neurodegenerative disorders, heart disease, and diabetes. It is also a potential biomarker for these conditions, as its levels have been found to be elevated in individuals with these diseases.

One of the key features of GJA10 is its role in the regulation of ion and water transport. It is a transmembrane protein that is involved in the formation of ion channels, which are critical for the regulation of the movement of charged particles, such as ions and water molecules, through the cell membrane. GJA10 is also involved in the regulation of the volume of the cell, which is critical for maintaining normal cell shape and function.

GJA10 has been shown to play a key role in the development and progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the formation of aggregates of neurotransmitters, such as beta-amyloid and tau, which are thought to contribute to the symptoms of these conditions.

GJA10 has also been shown to be involved in the regulation of heart function and is expressed in the heart muscle. It is involved in the regulation of the contractions of the heart muscle and has been shown to play a role in the development of heart failure.

In addition to its involvement in neurodegenerative disorders and heart disease, GJA10 has also been shown to be involved in the regulation of diabetes. It is a target for several diabetes medications, including insulin, and has been shown to be involved in the regulation of insulin sensitivity.

GJA10 is also a potential biomarker for several diseases, including neurodegenerative disorders, heart disease, and diabetes. Its levels have been found to be elevated in individuals with these conditions, and it has been shown to be involved in the regulation of various physiological processes that are important for the development and progression of these conditions.

In conclusion, GJA10 is a protein that has been identified as a potential drug target and biomarker for a variety of diseases. Its involvement in the regulation of ion and water transport, as well as its involvement in the regulation of neurodegenerative disorders, heart disease, and diabetes, make it an attractive target for further research and development. Further studies are needed to fully understand the role of GJA10 in these conditions and to develop safe and effective treatments.

Protein Name: Gap Junction Protein Alpha 10

Functions: One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell. Involved in tracer coupling between horizontal cells of the retina. May play a role in the regulation of horizontal cell patterning (By similarity)

The "GJA10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GJA10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets